JP2016507493A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016507493A5 JP2016507493A5 JP2015548291A JP2015548291A JP2016507493A5 JP 2016507493 A5 JP2016507493 A5 JP 2016507493A5 JP 2015548291 A JP2015548291 A JP 2015548291A JP 2015548291 A JP2015548291 A JP 2015548291A JP 2016507493 A5 JP2016507493 A5 JP 2016507493A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- neuropathic pain
- egfr
- group
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000004296 neuralgia Diseases 0.000 claims description 57
- 208000021722 neuropathic pain Diseases 0.000 claims description 55
- 208000002193 Pain Diseases 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 18
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 18
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 18
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 14
- 229960001972 panitumumab Drugs 0.000 claims description 14
- 229960005395 cetuximab Drugs 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 11
- 231100000331 toxic Toxicity 0.000 claims description 10
- 230000002588 toxic effect Effects 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 9
- 229960002584 gefitinib Drugs 0.000 claims description 9
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 9
- 208000011580 syndromic disease Diseases 0.000 claims description 9
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 8
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 8
- 229960001433 erlotinib Drugs 0.000 claims description 8
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 8
- 238000001802 infusion Methods 0.000 claims description 8
- 230000000202 analgesic effect Effects 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 230000002458 infectious effect Effects 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 230000002503 metabolic effect Effects 0.000 claims description 6
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 6
- 230000000472 traumatic effect Effects 0.000 claims description 6
- 230000001363 autoimmune Effects 0.000 claims description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 4
- 206010010356 Congenital anomaly Diseases 0.000 claims description 4
- -1 EGFR small molecule Chemical class 0.000 claims description 4
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 4
- JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 229960001686 afatinib Drugs 0.000 claims description 4
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 4
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 4
- 229930003827 cannabinoid Natural products 0.000 claims description 4
- 239000003557 cannabinoid Substances 0.000 claims description 4
- 229940111134 coxibs Drugs 0.000 claims description 4
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 229960003667 flupirtine Drugs 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 229960002870 gabapentin Drugs 0.000 claims description 4
- 229960004891 lapatinib Drugs 0.000 claims description 4
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 4
- 230000007774 longterm Effects 0.000 claims description 4
- 229950008001 matuzumab Drugs 0.000 claims description 4
- 229950008835 neratinib Drugs 0.000 claims description 4
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 229950010203 nimotuzumab Drugs 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 229960005489 paracetamol Drugs 0.000 claims description 4
- 229960001233 pregabalin Drugs 0.000 claims description 4
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 4
- 230000003637 steroidlike Effects 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 208000025966 Neurological disease Diseases 0.000 claims description 3
- 208000003130 Alcoholic Neuropathy Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 208000002720 Malnutrition Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010036105 Polyneuropathy Diseases 0.000 claims description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 2
- 208000008765 Sciatica Diseases 0.000 claims description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 2
- 208000020701 alcoholic polyneuropathy Diseases 0.000 claims description 2
- 229910052785 arsenic Inorganic materials 0.000 claims description 2
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims description 2
- 239000010425 asbestos Substances 0.000 claims description 2
- 230000003376 axonal effect Effects 0.000 claims description 2
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims description 2
- 206010010121 compartment syndrome Diseases 0.000 claims description 2
- 230000006835 compression Effects 0.000 claims description 2
- 238000007906 compression Methods 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 229960003350 isoniazid Drugs 0.000 claims description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 210000003666 myelinated nerve fiber Anatomy 0.000 claims description 2
- 210000004126 nerve fiber Anatomy 0.000 claims description 2
- 231100000862 numbness Toxicity 0.000 claims description 2
- 235000018343 nutrient deficiency Nutrition 0.000 claims description 2
- 229940124636 opioid drug Drugs 0.000 claims description 2
- 230000007824 polyneuropathy Effects 0.000 claims description 2
- 229910052895 riebeckite Inorganic materials 0.000 claims description 2
- 230000001953 sensory effect Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 229910052716 thallium Inorganic materials 0.000 claims description 2
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 claims description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003495 thiamine Drugs 0.000 claims description 2
- 235000019157 thiamine Nutrition 0.000 claims description 2
- 239000011721 thiamine Substances 0.000 claims description 2
- 230000003156 vasculitic effect Effects 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims 7
- 229940126586 small molecule drug Drugs 0.000 claims 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 238000002638 palliative care Methods 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- 208000008035 Back Pain Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- 230000002354 daily effect Effects 0.000 claims 1
- 230000003203 everyday effect Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 229960000513 necitumumab Drugs 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 claims 1
- 229950008250 zalutumumab Drugs 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 description 5
- 230000008827 biological function Effects 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940065144 cannabinoids Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261740876P | 2012-12-21 | 2012-12-21 | |
| US61/740,876 | 2012-12-21 | ||
| PCT/EP2013/003931 WO2014095088A1 (en) | 2012-12-21 | 2013-12-20 | Egfr targeted therapy of neurological disorders and pain |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018197322A Division JP2019023227A (ja) | 2012-12-21 | 2018-10-19 | 神経障害及び疼痛のｅｇｆｒ標的治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016507493A JP2016507493A (ja) | 2016-03-10 |
| JP2016507493A5 true JP2016507493A5 (enExample) | 2017-02-09 |
Family
ID=50002662
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015548291A Pending JP2016507493A (ja) | 2012-12-21 | 2013-12-20 | 神経障害及び疼痛のｅｇｆｒ標的治療 |
| JP2018197322A Pending JP2019023227A (ja) | 2012-12-21 | 2018-10-19 | 神経障害及び疼痛のｅｇｆｒ標的治療 |
| JP2022006083A Pending JP2022058654A (ja) | 2012-12-21 | 2022-01-19 | 神経障害及び疼痛のｅｇｆｒ標的治療 |
| JP2024026738A Pending JP2024069254A (ja) | 2012-12-21 | 2024-02-26 | 神経障害及び疼痛のｅｇｆｒ標的治療 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018197322A Pending JP2019023227A (ja) | 2012-12-21 | 2018-10-19 | 神経障害及び疼痛のｅｇｆｒ標的治療 |
| JP2022006083A Pending JP2022058654A (ja) | 2012-12-21 | 2022-01-19 | 神経障害及び疼痛のｅｇｆｒ標的治療 |
| JP2024026738A Pending JP2024069254A (ja) | 2012-12-21 | 2024-02-26 | 神経障害及び疼痛のｅｇｆｒ標的治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20150320861A1 (enExample) |
| EP (1) | EP2935333A1 (enExample) |
| JP (4) | JP2016507493A (enExample) |
| KR (1) | KR102228358B1 (enExample) |
| CN (1) | CN104968680A (enExample) |
| AU (1) | AU2013362134B2 (enExample) |
| BR (1) | BR112015013849A2 (enExample) |
| CA (1) | CA2891855A1 (enExample) |
| EA (1) | EA037709B1 (enExample) |
| IL (1) | IL239542B (enExample) |
| MX (1) | MX376166B (enExample) |
| WO (1) | WO2014095088A1 (enExample) |
| ZA (1) | ZA201503579B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11197862B2 (en) | 2015-07-16 | 2021-12-14 | Xomics Biopharma, Inc. | Methods of preventing toxicity of platinum drugs |
| AU2017363598A1 (en) * | 2016-11-22 | 2019-05-23 | Ovid Therapeutics Inc. | Methods of treating developmental disorders and/or seizure disorders with flupirtine |
| CU24555B1 (es) | 2018-05-07 | 2021-12-08 | Centro De Investig Y Desarrollo De Medicamentos Cidem | Combinación a dosis fija de paracetamol:amitriptilina |
| WO2020115108A1 (en) | 2018-12-06 | 2020-06-11 | Sørlandet Sykehus Hf | Egfr inhibitors and their use in the treatment of neuroathic pain |
| WO2021191094A1 (en) | 2020-03-24 | 2021-09-30 | University Court Of The University Of Edinburgh | Erbb-targeted therapies for neuropathic pain |
| TWI807338B (zh) * | 2020-06-26 | 2023-07-01 | 美商美國禮來大藥廠 | 結合ＴＧＦ-α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體於治療疼痛之用途 |
| KR102536315B1 (ko) * | 2020-09-11 | 2023-05-25 | 아주대학교산학협력단 | 네라티닙을 유효성분으로 포함하는 퇴행성 관절염 예방 또는 치료용 조성물 |
| TWI859538B (zh) * | 2021-05-21 | 2024-10-21 | 美商美國禮來大藥廠 | 靶向表皮調節素(epiregulin)之化合物及方法 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| KR100240308B1 (ko) | 1991-03-06 | 2000-01-15 | 플레믹 크리스티안 | 인간화된단클론성항체및혼성단클론성항체 |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0603194A4 (en) * | 1991-07-05 | 1994-12-07 | Seragen Inc | TO THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR TARGETED MOLECULES FOR TREATING INFLAMMABLE ARTHRITIS. |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5461146A (en) | 1992-07-24 | 1995-10-24 | Cephalon, Inc. | Selected protein kinase inhibitors for the treatment of neurological disorders |
| GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
| ATE165097T1 (de) | 1993-05-28 | 1998-05-15 | Cephalon Inc | Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen |
| WO1995034671A1 (en) | 1994-06-10 | 1995-12-21 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
| US5594009A (en) | 1994-10-14 | 1997-01-14 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| US5705511A (en) | 1994-10-14 | 1998-01-06 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| US5475110A (en) | 1994-10-14 | 1995-12-12 | Cephalon, Inc. | Fused Pyrrolocarbazoles |
| US5591855A (en) | 1994-10-14 | 1997-01-07 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| AU704391B2 (en) | 1994-10-28 | 1999-04-22 | Trustees Of The University Of Pennsylvania, The | Improved adenovirus and methods of use thereof |
| US5872154A (en) | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
| US5707618A (en) | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
| US5650407A (en) | 1995-04-05 | 1997-07-22 | Cephalon, Inc. | Selected soluble esters of hydroxyl-containing indolocarbazoles |
| US6019978A (en) | 1995-06-05 | 2000-02-01 | The Wistar Institute Of Anatomy And Biology | Replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
| CA2222140C (en) | 1995-06-15 | 2010-11-23 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US5994132A (en) | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
| US5830730A (en) | 1997-05-08 | 1998-11-03 | The Regents Of The University Of California | Enhanced adenovirus-assisted transfection composition and method |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
| JP2003528029A (ja) | 1998-08-14 | 2003-09-24 | アヴェンティス ファーマシューティカルズ インコーポレイテッド | 遺伝子治療用のアデノウイルス配合物 |
| AU773202B2 (en) | 1998-08-27 | 2004-05-20 | Aventis Pharma S.A. | Targeted adenovirus vectors for delivery of heterologous genes |
| AU2001268513A1 (en) | 2000-06-17 | 2002-01-02 | Third Wave Technologies, Inc. | Nucleic acid accessible hybridization sites |
| CZ302719B6 (cs) | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
| KR20040022449A (ko) | 2001-07-12 | 2004-03-12 | 유니버시티 오브 매사추세츠 | 유전자 불활성화를 매개하는 소형 간섭 ｒｎａ의 생체내제조 |
| AU2003211058A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TARGET DISCOVERY AND TARGET VALIDATION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP1546397A4 (en) | 2002-09-27 | 2007-10-31 | Cold Spring Harbor Lab | CELL BASED RNA INTERFERENCE AND ASSOCIATED METHODS AND COMPOSITIONS |
| US20040147428A1 (en) * | 2002-11-15 | 2004-07-29 | Pluenneke John D. | Methods of treatment using an inhibitor of epidermal growth factor receptor |
| GB0320793D0 (en) * | 2003-09-05 | 2003-10-08 | Astrazeneca Ab | Chemical process |
| WO2005038054A1 (en) | 2003-10-20 | 2005-04-28 | Zicai Liang | METHOD OF MEASURING THE EFFICACY OF siRNA MOLECULES |
| GB0327726D0 (en) | 2003-11-28 | 2003-12-31 | Isis Innovation | Method |
| AU2005232657B2 (en) | 2004-04-08 | 2010-12-16 | David B. Agus | ErbB antagonists for pain therapy |
| AU2005316458B2 (en) | 2004-12-17 | 2011-04-07 | Beth Israel Deaconess Medical Center | Compositions for bacterial mediated gene silencing and methods of using same |
| US7741273B2 (en) * | 2006-04-13 | 2010-06-22 | Warsaw Orthopedic, Inc. | Drug depot implant designs |
| US20100062994A1 (en) | 2006-07-14 | 2010-03-11 | Santaris Pharma A/S | Adenosine Receptor Antagonists |
| CU23526B6 (es) * | 2006-10-03 | 2010-05-19 | Ct Ingenieria Genetica Biotech | Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética |
| CA2666191C (en) | 2006-10-09 | 2017-07-11 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of pcsk9 |
| CA2666981A1 (en) | 2006-10-20 | 2008-05-02 | Ercole Biotech, Inc. | Soluble tnf receptors and their use in treatment of disease |
| US8501740B2 (en) * | 2007-10-09 | 2013-08-06 | Board Of Regents, The University Of Texas System | Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inhibitors of certain growth factor receptors |
| CA2741089A1 (en) * | 2008-10-22 | 2010-04-29 | Genentech, Inc. | Modulation of axon degeneration |
| US9908884B2 (en) * | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
| US8828391B2 (en) * | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| JP2014520792A (ja) * | 2011-07-06 | 2014-08-25 | スィーケフス ソールラン ホーエフ | Ｅｇｆｒ標的治療 |
-
2013
- 2013-12-20 MX MX2015007719A patent/MX376166B/es active IP Right Grant
- 2013-12-20 KR KR1020157019856A patent/KR102228358B1/ko active Active
- 2013-12-20 US US14/654,180 patent/US20150320861A1/en not_active Abandoned
- 2013-12-20 JP JP2015548291A patent/JP2016507493A/ja active Pending
- 2013-12-20 EA EA201500670A patent/EA037709B1/ru unknown
- 2013-12-20 CN CN201380067506.8A patent/CN104968680A/zh active Pending
- 2013-12-20 CA CA2891855A patent/CA2891855A1/en not_active Abandoned
- 2013-12-20 WO PCT/EP2013/003931 patent/WO2014095088A1/en not_active Ceased
- 2013-12-20 EP EP13824308.4A patent/EP2935333A1/en not_active Withdrawn
- 2013-12-20 BR BR112015013849A patent/BR112015013849A2/pt not_active Application Discontinuation
- 2013-12-20 AU AU2013362134A patent/AU2013362134B2/en not_active Ceased
-
2015
- 2015-05-21 ZA ZA2015/03579A patent/ZA201503579B/en unknown
- 2015-06-18 IL IL239542A patent/IL239542B/en active IP Right Grant
-
2016
- 2016-09-20 US US15/270,525 patent/US10611844B2/en active Active
-
2018
- 2018-10-19 JP JP2018197322A patent/JP2019023227A/ja active Pending
-
2020
- 2020-03-19 US US16/824,108 patent/US11396548B2/en active Active
-
2022
- 2022-01-19 JP JP2022006083A patent/JP2022058654A/ja active Pending
- 2022-07-15 US US17/865,481 patent/US20230016235A1/en active Pending
-
2024
- 2024-02-26 JP JP2024026738A patent/JP2024069254A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pribish et al. | A review of nonanesthetic uses of ketamine | |
| Kim et al. | Low-dose naltrexone for chronic pain: update and systemic review | |
| JP2016507493A5 (enExample) | ||
| Mercadante et al. | Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study | |
| Movafegh et al. | Naloxone infusion and post‐hysterectomy morphine consumption: a double‐blind, placebo‐controlled study | |
| Braverman et al. | Using gabapentin to treat failed back surgery syndrome caused by epidural fibrosis: A report of 2 cases | |
| Silva Filho et al. | Analgesic effect of magnesium sulfate during total intravenous anesthesia: randomized clinical study | |
| Khafagy et al. | Efficacy of epidural dexamethasone versus fentanyl on postoperative analgesia | |
| JP2015187125A5 (enExample) | ||
| Chen et al. | Preoperative and postoperative analgesic techniques in the treatment of patients undergoing transabdominal hysterectomy: a preliminary randomized trial | |
| EP2387401A1 (en) | Method for treating colorectal cancer | |
| Ahn et al. | Analgesic efficacy of preemptive pregabalin administration in arthroscopic shoulder surgery: a randomized controlled trial | |
| FI3356386T3 (fi) | Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä | |
| Rimaz et al. | Effect of gabapentin on morphine consumption and pain after surgical debridement of burn wounds: a double-blind randomized clinical trial study | |
| Conn | The story behind the use of glucocorticoids in the treatment of rheumatoid arthritis | |
| Davidson et al. | Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index≥ 27 kg/m2 | |
| Moseley et al. | Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: pooled results from three phase III studies | |
| EP2341900B1 (en) | A medicinal product and treatment | |
| Tramèr et al. | Magnesium Bier's block for treatment of chronic limb pain: a randomised, double-blind, cross-over study | |
| Lamond et al. | Addition of droperidol to morphine administered by the patient-controlled analgesia method: what is the optimal dose? | |
| Marinangeli et al. | Improved cancer pain treatment using combined fentanyl‐TTS and tramadol | |
| Rakhman et al. | Repeated and escalating preoperative subanesthetic doses of ketamine for postoperative pain control in patients undergoing tumor resection: a randomized, placebo-controlled, double-blind trial | |
| KR20240069750A (ko) | 신경 장애의 치료 | |
| Gombotz et al. | Opiate sparing effect of fixed combination of diclophenac and orphenadrine after unilateral total hip arthroplasty: A double-blind, randomized, placebo-controlled, multi-centre clinical trial | |
| US11752143B2 (en) | Methods of using low dose naltrexone to treat chronic pain |